BioSpace News Archive

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar , Anixa’s Chief Executive Officer, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14 , 2021.

Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, today announces positive results of the phase Ib clinical trial of its lead compound CM-101 in nonalcoholic fatty liver disease (NAFLD) patients with normal liver function.

Industry Veteran Brings Over Three Decades of Experience Across Global Healthcare Landscape

BioMarin Pharmaceutical Inc. announced that management will participate in two upcoming virtual conferences.

DURECT Corporation announced the appointment of two new members to its board of directors, Gail J. Maderis, MBA and Mohammad Azab, M.D., M. Sc., MBA, two senior industry veterans with extensive drug development, clinical research and medical affairs experience.

Neuronaute® EEG System and IceCap® bring Comprehensive Remote Electroencephalography Monitoring Services to People Living with Neurological Disorders.

PharmaEssentia to Present at the 39 th Virtual Annual J.P. Morgan Healthcare Conference

DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 39 th annual J.P. Morgan Healthcare Conference on January 11, 2021. The live presentation, which will occur virtually, is scheduled to begin at approximately 11:40 AM EST and will be concurrently webcast. The link to the webcast will be available on the Dexcom IR

Nxt-ID, Inc., a provider of healthcare devices and services, announced that on January 4, 2021, it received written notice from the Office of General Counsel of The Nasdaq Stock Market LLC confirming that the Company has regained compliance with the applicable Nasdaq minimum bid price continued listing requirement and the matter is now closed.

Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announced today that Prof. Dr. Dolores J. Schendel, Chief Executive Officer and Chief Scientific Officer of Medigene, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event, on Wednesday, 6 January 2021 from 8:00 am EST. The pane